-transparent.png){kind=logo}
We evaluated the efficacy of epirubicin in a phase II trial in breast cancer, as well as its cardiac toxicity. The study was carried out on 40 female patients with advanced, metastatic, or recurrent breast cancer. The patients were grouped into two groups: group I received 30 mg/m2 epirubicin weekly, and group II 90 mg/m2 epirubicin every 3 weeks. Cardiac monitoring was by ECG, roentgenography, echocardiography and endomyocardial biopsies. Clinical results were 35.3% overall response in group I, and 50% overall response in group II. No untoward cardiac toxicities were encountered. We conclude that epirubicin is an effective agent in breast cancer with relatively little cardiac toxicity.
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
October 2002,
Anti-cancer drugs,
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
June 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
February 1986,
Cancer treatment reports,
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
January 2004,
Anti-cancer drugs,
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
January 1996,
European journal of cancer (Oxford, England : 1990),
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
July 2001,
Breast cancer research and treatment,
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
October 2006,
Breast (Edinburgh, Scotland),
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
January 2006,
Clinical drug investigation,
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
July 1990,
Annals of oncology : official journal of the European Society for Medical Oncology,
N G el Mawla, and
M R Hamza, and
A el Khodari, and
H Khaled, and
R Gaafar, and
H el Zawahry, and
A abdel Wareth, and
M D Dardir, and
N Habboubi
September 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
